CapsoVision, Inc. Stock Price, News & Analysis

CapsoVision (NASDAQ: CV) reported third quarter 2025 results for the period ended September 30, 2025. Q3 revenue was $3.5 million, a 19% increase year‑over‑year, driven by higher CapsoCam Plus capsule sales and new accounts up 31%. Gross profit rose to $1.9 million (up $0.3 million; 54% gross margin). Operating expenses increased to $9.9 million, reflecting R&D with Canon, higher G&A costs and public‑company expenses. Cash and cash equivalents totaled $17.8 million; the company completed an IPO in July 2025 with $23.4 million net proceeds. The company filed for Breakthrough Device Designation for an early pancreatic cancer capsule and began enrollment for a new colon‑capsule study.

CapsoVision (NASDAQ: CV) announced it submitted a Breakthrough Device Designation (BDD) application to the FDA on Nov 6, 2025 for its CapsoCam UGI capsule endoscopy system to support earlier detection of pancreatic ductal adenocarcinoma.

The non-invasive, swallowed capsule provides panoramic imaging to visualize the duodenal papilla, a potential early indicator of pancreatic abnormalities, and streams images to a secure cloud for physician review. The company said the BDD could accelerate development, help shape clinical studies, and speed regulatory review.

The release highlights pancreatic cancer's poor prognosis (five-year survival as low as 8–10%), that ~80% of diagnoses occur at advanced stages, and the absence of recommended non-invasive screening for the general population.

CapsoVision (NASDAQ: CV) announced the appointment of David Garcia as Senior Vice President of Finance, effective November 3, 2025. Garcia brings more than 20 years of finance leadership across corporate finance, capital markets and strategic transactions.

His prior roles include Vice President of Financial Planning and Analysis at Matterport, where he helped lead its initial public offering and supported a recent acquisition, plus senior finance positions at View, Intelepeer Cloud Communications, and Align Technology, and earlier roles at Oracle and Deloitte. Management says his capital markets and cash-management experience will support CapsoVision's development pipeline and disciplined growth. Garcia holds an MBA in Finance from Wharton and a BA in Economics from Stanford.

CapsoVision (NASDAQ: CV) will release its third quarter 2025 financial results on Thursday, November 13, 2025 after market close. The company will host a conference call and live webcast on the same day at 1:30 pm PT / 4:30 pm ET to discuss results and provide a corporate update.

Dial-in details: domestic (800) 715-9871, international (646) 307-1963, conference ID 2181260. The webcast link and replay registration are available on the Events page in the investor relations section of the company website. The webcast replay will remain available for one year following the call.

CapsoVision (NASDAQ: CV), a medical technology company specializing in advanced imaging and AI-enabled capsule endoscopy solutions, has announced its participation in the upcoming 4th Annual ROTH Healthcare Opportunities Conference.

The conference will take place on October 9, 2025, in New York, NY. Company representatives Johnny Wang, President and CEO, and Doug Atkinson, Head of Global Sales, will be available for one-on-one meetings with interested parties during the event.

CapsoVision (NASDAQ: CV), a medical technology company specializing in AI-enabled capsule endoscopy solutions, reported strong Q2 2025 results with revenue of $3.3 million, up 17% year-over-year. The company achieved significant milestones, including a 75% growth in new accounts and reaching over 143,000 patients using CapsoCam Plus.

Key developments include submitting a 510(k) notification to FDA for CapsoCam Colon in June 2025 and completing an IPO in July 2025 that raised $23.4 million in net proceeds. The company reported a gross margin of 55% and operating expenses of $6.5 million, showing a decrease from Q2 2024 due to completed clinical trials.

CapsoVision (NASDAQ: CV), a commercial-stage medical technology company specializing in advanced imaging and AI-powered capsule endoscopy solutions, has scheduled its second quarter 2025 financial results release for Thursday, August 14, 2025, after market close.

The company will host a conference call and live webcast at 4:30 PM ET on the same day. Investors can access the call by dialing (800) 715-9871 (domestic) or (646) 307-1963 (international) with conference ID 1668374. A webcast will be available in the investor relations section of CapsoVision's website.

CapsoVision (NASDAQ: CV), a medical technology company specializing in capsule endoscopy solutions with advanced imaging and AI technologies, has successfully completed its Initial Public Offering (IPO). The company offered 5.5 million shares at $5.00 per share, raising gross proceeds of $27.5 million.

Trading commenced on the Nasdaq Capital Market on July 2, 2025, under the ticker symbol "CV". The underwriters, The Benchmark Company and Roth Capital Partners, have a 30-day option to purchase up to 825,000 additional shares at the IPO price, less underwriting discounts and commissions.

CapsoVision (NASDAQ: CV), a commercial-stage medical technology company specializing in advanced imaging and AI-powered capsule endoscopy solutions, has announced the pricing of its initial public offering (IPO). The company is offering 5,500,000 shares of common stock at $5.00 per share.

Trading is set to commence on the Nasdaq Capital Market on July 2, 2025, under the ticker symbol "CV". The offering, expected to close on July 3, 2025, aims to raise approximately $27.5 million in gross proceeds before deducting underwriting costs and other expenses. The underwriters have a 30-day option to purchase up to 825,000 additional shares at the IPO price.

The Benchmark Company and Roth Capital Partners are serving as joint book-running managers for the offering, which will be conducted through a prospectus as part of an SEC-approved registration statement.